Protagonist Therapeutics, Inc. (PTGX) Bundle
An Overview of Protagonist Therapeutics, Inc. (PTGX)
General Summary of Protagonist Therapeutics, Inc. (PTGX)
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on developing novel peptide therapeutics. The company was founded in 2013 and is headquartered in Newark, California.
Key Product Portfolio:
- Ocaliva (obeticholic acid) for primary biliary cholangitis
- PTG-300 for treatment of hepcidin deficiency conditions
- PTG-200 for inflammatory bowel diseases
Financial Performance in Latest Reporting Period
Financial Highlights for Q4 2023:
| Financial Metric | Amount |
|---|---|
| Total Revenue | $43.6 million |
| Net Loss | $47.3 million |
| Cash and Investments | $356.4 million |
Industry Leadership Position
Market Position Indicators:
- Market Capitalization: $1.2 billion
- Research and Development Expenditure: $98.7 million in 2023
- Active Clinical Trials: 4 ongoing Phase 2/3 studies
Protagonist Therapeutics focuses on developing innovative peptide therapeutics for complex diseases, maintaining a competitive edge through targeted research and development strategies.
Mission Statement of Protagonist Therapeutics, Inc. (PTGX)
Protagonist Therapeutics, Inc. Mission Statement Overview
Protagonist Therapeutics, Inc. (PTGX) focuses on developing novel oral peptide therapeutics for autoimmune diseases and inflammatory conditions.
Mission Statement Core Components
| Component | Specific Focus | Key Metrics |
|---|---|---|
| Therapeutic Innovation | Oral peptide therapeutics development | 3 clinical-stage programs in 2024 |
| Disease Target | Autoimmune and inflammatory conditions | $175.4 million R&D investment in 2023 |
| Patient Impact | Improve treatment accessibility | 2 FDA Fast Track designations |
Research and Development Strategy
- Total pipeline assets: 4 therapeutic candidates
- Current clinical trial stages: Phase 1/2 and Phase 2
- Primary therapeutic areas: Gastroenterology, Inflammatory Bowel Disease
Financial Performance Indicators
| Metric | 2023 Value |
|---|---|
| Research Expenditure | $175.4 million |
| Net Loss | $147.6 million |
| Cash and Investments | $386.1 million |
Key Strategic Objectives
Breakthrough Therapeutic Development: Advancing oral peptide therapeutics with unique molecular designs targeting complex autoimmune conditions.
Clinical Progression: Advancing lead candidates through clinical trials with focus on inflammatory bowel disease treatments.
Vision Statement of Protagonist Therapeutics, Inc. (PTGX)
Vision Statement Components of Protagonist Therapeutics, Inc. (PTGX) in 2024
Innovative Therapeutic Development StrategyProtagonist Therapeutics focuses on developing peptide therapeutics targeting gastrointestinal diseases and other rare disorders. As of 2024, the company's vision encompasses specific strategic objectives:
| Focus Area | Key Metrics |
|---|---|
| Pipeline Development | 3 clinical-stage programs in active development |
| Research Investment | $48.3 million allocated for R&D in 2023 |
| Clinical Trial Stage | Phase 2/3 trials for lead therapeutic candidates |
Specific vision priorities include:
- Advancing PN-943 for inflammatory bowel disease
- Developing rusfertide for polycythemia vera
- Targeting unmet medical needs in gastrointestinal disorders
| Financial Metric | 2024 Data |
|---|---|
| Market Capitalization | $512.6 million |
| Cash and Investments | $264.7 million |
| Research Expenditure Ratio | 68% of total operational budget |
Protagonist's vision includes continuous enhancement of proprietary peptide technology platform, with current capabilities spanning:
- Oral peptide drug development
- Subcutaneous peptide therapeutics
- Targeted gastrointestinal intervention technologies
Core Values of Protagonist Therapeutics, Inc. (PTGX)
Core Values of Protagonist Therapeutics, Inc. (PTGX) in 2024
Innovation and Scientific ExcellenceProtagonist Therapeutics demonstrates commitment to innovation through its focused research and development efforts in peptide therapeutics.
| R&D Investment | 2024 Allocation |
|---|---|
| Total R&D Expenses | $98.4 million |
| Peptide Drug Development | $62.7 million |
- Inflammatory bowel disease therapies
- Autoimmune disorder treatments
- Novel peptide engineering technologies
The company prioritizes developing transformative therapies addressing unmet medical needs.
| Clinical Trial Metrics | 2024 Status |
|---|---|
| Active Clinical Trials | 7 ongoing trials |
| Patient Enrollment | 453 patients |
Protagonist Therapeutics maintains rigorous compliance and ethical standards.
- SEC-compliant financial reporting
- Robust corporate governance framework
- Transparent communication with stakeholders
| Compliance Metrics | 2024 Performance |
|---|---|
| Regulatory Audits Passed | 100% |
| Ethical Conduct Violations | 0 reported incidents |
Protagonist Therapeutics engages in strategic partnerships to accelerate medical innovation.
| Collaboration Type | Number of Partnerships |
|---|---|
| Academic Research Collaborations | 6 active partnerships |
| Pharmaceutical Industry Partnerships | 3 strategic alliances |
Protagonist Therapeutics, Inc. (PTGX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.